Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM

被引：5
|
作者：
Ohwaki, Kenji
Furihata, Kenichi
Mimura, Hanaka
Oura, Tomonori
Imaoka, Takeshi
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1024-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1024-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [2] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycaemic control and body weight in Japanese patients with type 2 diabetes
    Benson, C. T.
    Ohwaki, K.
    Furihata, K.
    Mimura, H.
    Oura, T.
    Imaoka, T.
    DIABETOLOGIA, 2019, 62 : S353 - S353
  • [3] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [4] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    JCI INSIGHT, 2020, 5 (17)
  • [5] Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
    Rangraze, Imran Rashid
    Khan, Shehla
    Wali, Adil Farooq
    Menezes, Godfred
    Goud, Manjunatha
    Jabran, Muhammad
    CURRENT DRUG SAFETY, 2024,
  • [6] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients
    Zhao, L.
    Wen, Q.
    Zhang, Y.
    Yu, G.
    Pan, T.
    Wang, Y.
    Li, F.
    Jin, P.
    Jiang, H.
    Zeng, M.
    Li, X.
    Li, X.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [7] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [8] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [9] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Jennifer Martin
    Corina Loghin
    Clinical Pharmacokinetics, 2021, 60 : 1049 - 1059
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Xiaosu Ma
    Jennifer A. Martin
    Charles T. Benson
    Clinical Pharmacokinetics, 2022, 61 : 1057 - 1067
12345